Targeting Notch in Oncology: The Path Forward

Authors

Samarpan Majumder, LSU Health Sciences Center- New OrleansFollow
Judy S. Crabtree, LSU Health Sciences Center- New OrleansFollow
Todd E. Golde, University of Florida
Lisa M. Minter, University of Massachusetts Amherst
Barbara A. Osborne, University of Massachusetts Amherst
Lucio Miele, LSU Health Sciences Center- New OrleansFollow

Document Type

Article

Publication Date

12-8-2020

Publication Title

Nature Reviews Drug Discovery

Abstract

Notch signalling is involved in many aspects of cancer biology, including angiogenesis, tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can function as an oncogene and a tumour suppressor in different cancers and in different cell populations within the same tumour. Despite promising preclinical results and early-phase clinical trials, the goal of developing safe, effective, tumour-selective Notch-targeting agents for clinical use remains elusive. However, our continually improving understanding of Notch signalling in specific cancers, individual cancer cases and different cell populations, as well as crosstalk between pathways, is aiding the discovery and development of novel investigational Notch-targeted therapeutics.

First Page

125

Last Page

144

PubMed ID

33293690

Volume

20

Issue

2

Publisher

Nature Research

Recommended Citation

Majumder, Samarpan; Crabtree, Judy S.; Golde, Todd E.; Minter, Lisa M.; Osborne, Barbara A.; and Miele, Lucio, "Targeting Notch in Oncology: The Path Forward" (2020). School of Medicine Faculty Publications. 186.
https://digitalscholar.lsuhsc.edu/som_facpubs/186
10.1038/s41573-020-00091-3